Therapeutic considerations: Rating scales

Richard Rudick; Brian G. Weinshenker; Gary Cutter

Therapeutic considerations: Rating scales

Richard Rudick, Brian G. Weinshenker, Gary Cutter

Neurology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

I. INTRODUCTION Quantifying the clinical impact of multiple sclerosis (MS) is necessary for a number of reasons. Clinical assessment tools are needed for patient care. If not for clinical outcome assessments, how would a neurologist determine disease severity or the effect of treatment? Clinical assessment tools are also indispensable for judging experimental therapies. If not for clinical assessment tools, how would investigators measure the effectiveness of an intervention?.

Original language	English (US)
Title of host publication	Handbook of Multiple Sclerosis, Third Edition
Publisher	CRC Press
Pages	465-491
Number of pages	27
ISBN (Electronic)	9780824741846
ISBN (Print)	9780824704858
State	Published - Jan 1 2001

ASJC Scopus subject areas

General Medicine

Cite this

@inbook{b5d1e9fb27ad4febaf4d39fa79b856cc,

title = "Therapeutic considerations: Rating scales",

abstract = "I. INTRODUCTION Quantifying the clinical impact of multiple sclerosis (MS) is necessary for a number of reasons. Clinical assessment tools are needed for patient care. If not for clinical outcome assessments, how would a neurologist determine disease severity or the effect of treatment? Clinical assessment tools are also indispensable for judging experimental therapies. If not for clinical assessment tools, how would investigators measure the effectiveness of an intervention?.",

author = "Richard Rudick and Weinshenker, {Brian G.} and Gary Cutter",

note = "Publisher Copyright: {\textcopyright} 2001 by Taylor & Francis Group, LLC.",

year = "2001",

month = jan,

day = "1",

language = "English (US)",

isbn = "9780824704858",

pages = "465--491",

booktitle = "Handbook of Multiple Sclerosis, Third Edition",

publisher = "CRC Press",

}

TY - CHAP

T1 - Therapeutic considerations

T2 - Rating scales

AU - Rudick, Richard

AU - Weinshenker, Brian G.

AU - Cutter, Gary

PY - 2001/1/1

Y1 - 2001/1/1

N2 - I. INTRODUCTION Quantifying the clinical impact of multiple sclerosis (MS) is necessary for a number of reasons. Clinical assessment tools are needed for patient care. If not for clinical outcome assessments, how would a neurologist determine disease severity or the effect of treatment? Clinical assessment tools are also indispensable for judging experimental therapies. If not for clinical assessment tools, how would investigators measure the effectiveness of an intervention?.

AB - I. INTRODUCTION Quantifying the clinical impact of multiple sclerosis (MS) is necessary for a number of reasons. Clinical assessment tools are needed for patient care. If not for clinical outcome assessments, how would a neurologist determine disease severity or the effect of treatment? Clinical assessment tools are also indispensable for judging experimental therapies. If not for clinical assessment tools, how would investigators measure the effectiveness of an intervention?.

UR - http://www.scopus.com/inward/record.url?scp=85018040465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018040465&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85018040465

SN - 9780824704858

SP - 465

EP - 491

BT - Handbook of Multiple Sclerosis, Third Edition

PB - CRC Press

ER -

Therapeutic considerations: Rating scales

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this